← Browse by Condition
Medical Condition

human papillomavirus related neck squamous cell carcinoma of unknown primary

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for human papillomavirus related neck squamous cell carcinoma of unknown primary sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — human papillomavirus related neck squamous cell carcinoma of unknown primary Clinical Trials

How many clinical trials are currently recruiting for human papillomavirus related neck squamous cell carcinoma of unknown primary?
ClinicalMetric currently tracks 1 actively recruiting clinical trials for human papillomavirus related neck squamous cell carcinoma of unknown primary, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 1. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for human papillomavirus related neck squamous cell carcinoma of unknown primary?
human papillomavirus related neck squamous cell carcinoma of unknown primary research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a human papillomavirus related neck squamous cell carcinoma of unknown primary clinical trial?
Eligibility criteria for human papillomavirus related neck squamous cell carcinoma of unknown primary trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Emory University 1 trial

Recruiting Clinical Trials

NCT06636734 Phase 2
Recruiting
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Enrollment
28 pts
Location
United States
Sponsor
Emory University
View Trial →

Related Conditions

clinical stage iv hpv mediated p16 positive oropharyngeal carcinoma ajcc v8 (1) metastatic head and neck squamous cell carcinoma (1) metastatic hypopharyngeal squamous cell carcinoma (1) metastatic laryngeal squamous cell carcinoma (1) metastatic nasopharyngeal squamous cell carcinoma (1) metastatic oral cavity squamous cell carcinoma (1) metastatic oropharyngeal squamous cell carcinoma (1) metastatic paranasal sinus squamous cell carcinoma (1) recurrent head and neck squamous cell carcinoma (1) recurrent hypopharyngeal squamous cell carcinoma (1) recurrent laryngeal squamous cell carcinoma (1) recurrent nasopharyngeal squamous cell carcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology